EGFR and neoplasm: EGFR-directed monoclonal antibodies such as cetuximab, necitumumab, panitumumab, matuzumab and nimotuzumab can bind on to EGFR present on the surface of tumor cells and prevent the binding of the ligand epidermal growth factor (EGF) in the extracellular domain, resulting in inhibition of EGFR signalling.